- In April 2024, OraSure Technologies, Inc., a U.S.-based leader in point-of-care diagnostic testing, announced the launch of an upgraded saliva-based COVID-19 and influenza combo test for home and clinical use. This next-generation product provides faster results and improved accuracy, aligning with increasing consumer demand for multi-pathogen, self-administered diagnostics. The development reflects OraSure’s commitment to enhancing public access to non-invasive testing solutions that support early detection and disease management
- In March 2024, Salimetrics, LLC, a Pennsylvania-based biotechnology company, expanded its clinical research applications by introducing saliva-based hormone and immune function test kits to academic and wellness institutions across North America. These kits are designed for non-invasive biomarker collection and analysis, supporting studies in stress, fertility, and chronic disease management. The initiative reinforces Salimetrics' position as a trusted provider of high-quality saliva testing solutions in both clinical and research domains
- In February 2024, Thermo Fisher Scientific Inc. partnered with U.S. public health departments to pilot saliva-based drug testing programs targeting substance abuse in community health centers and schools. This collaboration aims to provide rapid, low-cost, and minimally invasive testing to underserved populations, advancing the company’s role in supporting public health initiatives and enhancing early intervention efforts in addiction treatment
- In January 2024, Spectrum Solutions, LLC, a U.S. provider of molecular diagnostic collection devices, announced FDA emergency use authorization (EUA) for its saliva-based pathogen detection device that enables simultaneous screening of multiple viruses. This development signifies a leap forward in multiplex testing, offering clinical laboratories and at-home users a streamlined solution for broader infectious disease surveillance
- In January 2024, Everlywell, Inc., a prominent at-home diagnostics company, launched a saliva-based hormone testing kit focused on women's health, with digital result integration and telehealth support. This innovation highlights the growing trend toward personalized health monitoring and remote diagnostics, catering to consumer preferences for privacy, accessibility, and convenience in managing hormonal health and wellness
